This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Health Winners & Losers: Cardica

Health stocks fell Tuesday, but not quite so much as the broader markets.

The Nasdaq and Amex biotechnology indices were down 1.2% and 1.3%, respectively.

Bucking the trend, health stock Cardica (CRDC - Get Report) got approval for its PAS-Port system for use in cardiac bypass surgery. Shares surged 25.8% to $10.05.

Biodel (BIOD) shares continued to fall for a second day on late-stage study results on its diabetes drug Viaject. The data varied considerably in one of the study sites. Shares were off by 13% to $5.

Meanwhile, generic drugmaker Mylan (MYL - Get Report) said Monday after the market's close that it will retain its specialty drug business Dey LP following a strategic review, but will relocate its commercial operations to the East Coast from Napa, Calif. Mylan reaffirmed its adjusted earnings outlook for the next three years.

In a separate announcement, Mylan said it will offer $400 million in notes, due 2015, to institutional investors through a private offering to qualified buyers. The company said it will use the proceeds to pay down its credit security. Shares were off by 10.6% at $11.10.

Merck (MRK - Get Report) said Tuesday that a three-judge panel of the 3rd Circuit Court of Appeals voted 2-1 to reinstate a consolidated securities class action suit. The suit was originally brought by investors in connection with disclosures regarding Vioxx, but had been dismissed by a federal district court in April 2007.

Merck's shares were down by 3.2% to $34.34.

Some of Merck's pharma peers were hit harder. King Pharmaceutical's (KG) shares gave up 5.4%, to $11.02. And Schering-Plough (SGP) fell 5.1% to $18.63.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
BIOD $0.27 0.00%
CRDC $0.24 0.00%
MRK $49.38 0.00%
MYL $51.39 0.00%
AAPL $94.02 0.00%


Chart of I:DJI
DOW 16,204.97 -211.61 -1.29%
S&P 500 1,880.05 -35.40 -1.85%
NASDAQ 4,363.1440 -146.4150 -3.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs